Neptinib (NEP010) is an orally bioavailable afatinib derivative with potent antitumor activity. It strongly inhibits wild-type and mutant EGFR kinases, including L858R and T790M variants, and demonstrates significant suppression of tumor growth in NSCLC mouse models. This makes it a valuable tool for in vitro and in vivo oncology research targeting EGFR-driven cancers.